header mRNA report 540x680@2x
NICE INSIGHT REPORT

Messenger Ribonucleic Acid, mRNA:
2024 Market Insight, CDMO Pricing and Competitor Benchmarking

Published March, 2024
  • 2024 mRNA manufacturing pricing study—the first of its kind
  • Survey of clinical trials currently being conducted, segmented by type and treatment
  • SME analysis and forecasts of biotech fundraising
  • 68 CDMO profiles, including mRNA, chemically synthesized RNA, and LNP manufacturers
  • mRNA vaccines and therapeutic manufacturing challenges and innovations
header mRNA report 540x680@2x

Key market insights for innovators, CDMOs and investors in the mRNA industry.

01 benchmarking icon 65x65@2x

Essential price benchmarking and market intelligence for CDMOs

Compare prices to your competitors with our strategic pricing study, which breaks down the manufacturing process and industry costs. As investments pour in from both the private and government sectors, learn from leaders in mRNA-based drugs so you can better position your business.
02 analysis icon 65x65@2x

Grasp the mRNA Vaccine & Therapeutics Pipeline

Our Market Analysis provides an in-depth R&D pipeline report segmented by indication and development stage. Make informed business decisions with our guide to approved mRNA drugs and the developmental and clinical landscape. See where your competitors are from pre-clinical through Phase III trials.

Coming March, 2024

Our Market Analysis combines data insights and interviews with prominent mRNA players so your sales team can unlock the booming industry.

The Messenger Ribonucleic Acid, mRNA: 2024 Market Insight, CDMO Pricing and Competitor Benchmarking provides

01 pricing data icon 65x65@2x
Strategic pricing study that analyzes the manufacturing process and primary data
02 profiles icon 65x65@2x
Over 60 CDMO profiles which include segment, proprietary technologies and location
03 pie chart icon 65x65@2x
Market intelligence segmented by drug type and disease application
04 pipeline icon 65x65@2x
Pipeline development mapping for approved mRNA drugs and preclinical through phase III trials
05 data analytics icon 65x65@2x
Investor insights for one of the fastest growing markets in pharma
06 benefits icon 65x65@2x
Unique benefits and complexities to mRNA manufacturing that is invaluable to developers

Over 900 hours of data collection and analysis, with
invaluable insights from industry experts

Table of Contents

Executive Summary

Overview of the report

Study Methodology

Section I:

View from the Top: Success and Promise of the RNA Technology

Section II:

mRNA Manufacturing Process Overview

Section III:

Manufacturing Challenges and Innovation

Section IV:

Analytics Overview

Section V:

Regulatory Update

Section VI:

mRNA CDMOs Market Outlook

Section VII:

Strategic Pricing Study

Section VIII:

mRNA CDMO Profiles

mRNA report form@2x
Coming March, 2024
Request a quote for the Messenger Ribonucleic Acid, mRNA: 2024 Market Insight report

mRNA report form@2x